Valiant Labs Approves Audited Q3 FY26 Standalone & Consolidated Results
Valiant Laboratories Limited's Board approved audited standalone and consolidated financial results for Q3 FY26. The results for the quarter and nine months ended December 31, 2025, were approved on February 11, 2026.
Financial results are material information for investors and affect stock valuation and investment decisions.
The announcement is a routine disclosure of financial results and audit reports, with no specific positive or negative financial performance indicators highlighted in the summary.
Valiant Laboratories Limited announced the approval of its audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The Board of Directors considered and approved these results, along with the audit report issued by Raman S. Shah & Co., Chartered Accountants, during their meeting held on February 11, 2026.
The Board meeting commenced at 02:00 PM and concluded at 04:30 PM on February 11, 2026. The financial results will be available on the company's website, www.valiantlabs.in, and on the websites of BSE Limited and NSE Limited.
The company operates as a single-segment entity, engaged in the manufacturing of chemicals. The financial statements were reviewed by the Audit Committee before being approved by the Board.
What to do with a filing like this
Valiant Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Valiant Laboratories Limited. Read the original for the full detail.